ADVISORY BULLETIN

December 26, 2019

Bulletin Terminating the Effect of the MMLB March 2019 Resolution

On March 21, 2019, the Medical Marihuana Licensing Board (MMLB) adopted a Resolution on Marijuana Product Access for Patients. On April 30, 2019, Executive Order No. 2019-7 abolished the MMLB and transferred the authorities, powers, duties, functions and responsibilities of the MMLB under the Medical Marihuana Facilities Licensing Act (MMFLA) to the Marijuana Regulatory Agency (MRA).

Effective March 1, 2020:

- This advisory bulletin terminates the effect of the March 2019 Resolution on Marijuana Product Access for Patients.
- Licensees must continue to notify the MRA within one business day of becoming aware of any adverse reaction to a marijuana product sold or transferred.
- Until such time as the MRA publishes an advisory bulletin notifying all licensees that the effect of this bulletin has been terminated, the MRA will not take disciplinary action against a licensee in the following circumstances:

Growers and Processors

Licensees who obtain marijuana flower – defined as bud, shake and trim only – from registered primary caregivers must enter all inventory into the statewide monitoring system immediately upon receipt.

Licensees may only transfer marijuana flower that has been tested in full compliance with the law and administrative rules.

Licensees must tag or package all inventory that has been identified in the statewide monitoring system and must transfer marijuana flower by means of a secured transporter, except where exempted under the MMFLA.

Provisioning Centers

Licensees must obtain patient consent on a form provided by the MRA prior to selling any marijuana products obtained from a caregiver prior to April 1, 2019, that have not been tested in full compliance with the law and administrative rules. As of November 22, 2019, licensees must additionally test these products for Vitamin E Acetate, if intended for use by inhalation.